Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesUrologyAetna Vasectomy Procedures Coverage Update | OpenP…
    Ask Trek AI about this page
    CurrentAetnaPolicy 0027

    Vasectomy Procedures

    Customize your policy alerts

    Sign up for Aetna Policy 0027 alerts

    Get alerted when Policy 0027 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines Aetna's coverage stance for vasectomy-related procedures, including medical necessity for vasectomy reversal for post-vasectomy pain syndrome and procedures considered experimental/investigational. Applies to Aetna members subject to the payer's benefit rules.

    Policy Summary
    PayerAetna
    PolicyVasectomy Procedures
    Policy CodePolicy 0027
    Change TypeAnnual review (no material changes)
    Effective DateDec 7, 2004
    Last ReviewMar 6, 2023
    Next Review DateJan 11, 2024
    Key ActionDocument conservative treatments (NSAIDs and local nerve blocks/steroid injections) tried and failed before pursuing vasectomy reversal for post-vasectomy pain syndrome.
    SourceLink

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    500,000U.S. vasectomies/year
    1–2%PVPS incidence
    30–60%Reversal success range
    71%MDSC success (cohort)

    Coverage Criteria for Vasectomy-related Procedures

    Vasectomy reversal for post-vasectomy pain syndrome

    Covered when ALL of the following are met

    Reversal for PVPS criteria: Member has post-vasectomy pain syndrome (PVPS) AND has failed a trial of non-steroidal anti-inflammatory medications AND has failed local nerve blocks or steroid injections

    Per policy medical necessity statement; document (UpToDate) identifies NSAIDs and warm baths as first-line and nerve blocks/steroid injections as next-line treatments before considering surgery.

    Surgical treatment of PVPS (general criteria)

    Consider surgical intervention for PVPS after ALL of the following are met:

    PVPS surgical candidacy: 1) Persistent post-vasectomy scrotal or testicular pain consistent with PVPS after evaluation to rule out other causes of pain; 2) Failure of conservative and medical management (e.g., NSAIDs, warm baths, medical therapy, nerve blocks/steroid injections); 3) Patient counseling regarding risks, benefits, anticipated outcomes, alternative surgical options, and potential out-of-pocket costs; 4) Shared decision-making documenting patient understanding of uncertainty in long-term outcomes and expected need for alternative contraception if fertility restored.

    Based on retrospective series and reviews; timing to proceed to surgery is individualized and no standardized protocols exist.

    Indications for vasectomy reversal or other surgical interventions for PVPS

    Surgical interventions (including vasectomy reversal) for PVPS are considered after failure of conservative therapies and after exclusion of other causes of pain.

    Entry to surgical therapy for PVPS: Patient has chronic post-vasectomy scrotal or testicular pain (PVPS) AND other sources of scrotal/testicular pain have been evaluated and reasonably excluded AND conservative/medical management (for example NSAIDs and warm baths, with or without nerve blocks or steroid injections) has been tried and documented as unsuccessful OR the patient remains significantly impaired by pain despite noninvasive therapy.not specified

    Document emphasizes individualized decision-making; orchiectomy is a last-resort option with high rates of persistent pain in some series; no standardized timelines for conservative therapy duration are specified.

    Aetna considers several procedures experimental and investigational because peer-reviewed evidence is inadequate to establish effectiveness. Examples explicitly listed in the policy include endoscopic vasectomy and device- or clip-based occlusion methods such as the implantable vas deferens ligation clip (Vasclip). The policy names other novel occlusion approaches (e.g., Pro‑Vas occlusion) and percutaneous injection/occlusion techniques as investigational as well. These procedures are not supported as medically necessary due to limited clinical data and inconsistent results in the literature.

    Some vasal injection and occlusion techniques described in the literature rely on chemicals or polymers that are not available for use in the United States. For example, certain sclerosing agents used in dye-confirmation techniques and the polymer styrene maleic anhydride (SMA) used in RISUG have been studied abroad but are not approved or available in U.S. practice; clinical trials are ongoing for some of these methods.

    Orchiectomy is described in the evidence as a last‑resort option for patients with debilitating, refractory post‑vasectomy pain. The policy notes that despite being used as an extreme salvage measure, orchiectomy may be associated with a high rate of persistent pain in some series (for example, one study reported that 80% of patients continued to experience pain after orchiectomy), so it is not presented as a routinely effective solution.

    The policy states that the procedures and surgical treatments listed as experimental and investigational — including endoscopic vasectomy, Vasclip, Pro‑Vas, vasal injection methods (e.g., RISUG), intra‑vas plugs, LigaSure occlusion, and surgical PVPS treatments such as epididymectomy and micro‑denervation of the spermatic cord — are considered investigational and are not supported as medically necessary because of inadequate evidence.

    Endoscopic vasectomy and several novel endoluminal occlusion techniques remain investigational or preclinical. The available data are limited (often ex vivo or in small series, including porcine models and pilot device evaluations) and do not establish clinical utility or long‑term outcomes for these approaches.

    Within the provided document excerpts there are no discrete scenarios explicitly labeled as “not medically necessary.” Instead, the policy frames certain procedures as investigational due to inadequate evidence and documents clinical pathways and criteria for medically necessary interventions (for example, vasectomy reversal for refractory post‑vasectomy pain).

    Coding References

    Covered CPT CodesCPTCovered
    54860Epididymectomy; unilateral
    54861Epididymectomy; bilateral
    55400Vasovasostomy, vasovasorrhaphy
    55250Vasectomy, unilateral or bilateral (separate procedure), including postoperative semen examination(s)
    89310Semen analysis; motility and count (not including Huhner test)
    52402Cystourethroscopy with transurethral resection or incision of ejaculatory ducts
    ICD-10 Codes ReferencedICD-10
    N50.81Testicular pain
    Z30.2Encounter for sterilization
    Z98.52Vasectomy status
    G89.28Other chronic postprocedural pain [post-vasectomy]
    Procedure/Diagnosis codes mentioned (document does not list explicit codes)mixed
    No codes listed

    Provider Actions, Documentation & Prior Authorization

    Prior Authorization

    Verify prior authorization requirements for reversal-related procedures

    Certain CPT codes related to vasectomy reversal and related procedures are described as covered when selection criteria are met; providers should verify whether prior authorization is required with the member's plan before scheduling (examples in the policy include CPT 54860, 54861, 55400).

    • CPT examples listed in the policy: 54860, 54861, 55400
    • Providers must confirm authorization requirements with the payer for the member's specific benefit plan
    Note

    No prior authorization statements present in this section

    The policy text contains no explicit prior authorization statements for the procedures discussed; providers should not assume automatic authorization language is present in this section.

    • The document states there are no prior authorization statements in this section

    Background

    Vasectomy is a common outpatient sterilization procedure in which the vas deferens are occluded to prevent sperm transport; techniques vary and include no‑scalpel approaches, excision with ligation/cautery, clips, and a range of device‑ or injection‑based occlusion methods. Failure rates are generally low (0–2%), complication rates are uncommon (<3%), and the procedure is performed frequently (approximately 500,000 procedures annually in the U.S.). A minority of men develop chronic post‑vasectomy pain—post‑vasectomy pain syndrome (PVPS)—which is managed initially with conservative measures (NSAIDs, warm baths, nerve blocks/steroid injections) and, when refractory and appropriately evaluated, may be considered for surgical interventions such as vasectomy reversal.

    Definitions

    inv-26: Post-vasectomy pain syndrome (PVPS) — definition and ICD-10 reference
    DefinitionChronic testicular or scrotal pain that occurs after vasectomy and is distinct from routine post-procedure pain; often related to chronic congestive epididymitis, sperm granuloma, or nerve entrapment.
    ICD-10 referenceG89.28 — Other chronic postprocedural pain [post-vasectomy].
    Clinical noteFirst-line therapy includes NSAIDs and warm baths; if unsuccessful, local nerve blocks or steroid injections may be attempted before surgical options.
    inv-27: RISUG — definition (reversible inhibition of sperm via SMA polymer injection)
    DefinitionReversible Inhibition of Sperm Under Guidance (RISUG): percutaneous injection of the non‑sclerotic polymer styrene maleic anhydride (SMA) into the vas lumen intended to provide long‑term, potentially reversible contraception.
    Clinical status
    Policy Summary
    PayerAetna
    PolicyVasectomy Procedures
    Policy CodePolicy 0027
    Change TypeAnnual review (no material changes)
    Effective DateDec 7, 2004
    Last ReviewMar 6, 2023
    Next Review DateJan 11, 2024
    Key ActionDocument conservative treatments (NSAIDs and local nerve blocks/steroid injections) tried and failed before pursuing vasectomy reversal for post-vasectomy pain syndrome.
    SourceLink
    On This Page
    Coverage Criteria for Vasectomy-related ProceduresCoding ReferencesProvider Actions, Documentation & Prior AuthorizationBackgroundDefinitions
    Note

    Prior authorization rules not specified in these sections

    The policy chunks provided do not list specific CPT/HCPCS codes that universally require prior authorization or provide an explicit prior authorization ruleset; administrative verification is required per patient plan.

    • Administrative note: check the member's benefit plan for any authorization triggers or local payer rules
    Documentation Required

    Document prior conservative therapy before reversal

    Conservative therapies (e.g., NSAIDs and local nerve blocks/steroid injections) are expected to be tried and documented and must have failed before vasectomy reversal is considered medically necessary for PVPS.

    • Document trials of non-steroidal anti-inflammatory medications
    • Document attempted local nerve blocks or steroid injections and clinical response
    Step Therapy

    Escalate to surgery only after conservative management fails

    For PVPS, initial management should be conservative or medical; surgical options (including vasectomy reversal, epididymectomy, or micro-denervation of the spermatic cord) are considered only after failure of conservative measures and exclusion of other causes.

    • Ensure conservative/medical management has been attempted and failed before escalating to surgery
    • Evaluate and rule out other causes of scrotal/testicular pain prior to surgical referral
    Documentation Required

    Document conservative therapy attempted prior to surgery

    Before proceeding to surgical treatment for PVPS, document use of noninvasive measures such as NSAIDs, warm baths, nerve blocks or steroid injections and their clinical outcomes.

    • Record specific conservative modalities tried (NSAIDs, warm baths, nerve blocks/steroid injections)
    • Record duration and response to each conservative therapy
    Documentation Required

    Document failure of NSAIDs and local nerve interventions for VR necessity

    Medical necessity documentation for vasectomy reversal for PVPS must show failure of NSAIDs and local nerve blocks/steroid injections.

    • Include clinical notes documenting trial and failure of NSAIDs
    • Include records of local nerve block or steroid injection attempts and outcomes
    Documentation Required

    Vasal injection verification methods described in trials (research context)

    In research descriptions of vasal injection techniques, procedural verification methods such as dye testing with urinary excretion to confirm placement/occlusion are described; note that some chemicals used in these techniques are not available in the U.S.

    • Dye is injected into each vas with different colors and urinary excretion is observed to confirm occlusion
    • Some required chemicals for certain sclerosing techniques are not available in the United States
    Documentation Required

    Comprehensively document evaluation, counseling, and informed consent for VR in PVPS

    When pursuing vasectomy reversal for PVPS, documentation should include prior conservative treatment attempts, evaluation to exclude other causes of scrotal/testicular pain, patient counseling about expected outcomes and alternative contraception, and informed consent describing potential for persistent pain and surgical risks.

    • Document evaluation that rules out alternative sources of pain
    • Document counseling on success rates, need for alternative contraception, and risk of persistent pain
    Denial Risk

    Risk of denial for experimental/investigational procedures

    Procedures listed in the policy as experimental or investigational (e.g., endoscopic vasectomy, Vasclip, Pro-Vas, RISUG, Intra Vas Plug, LigaSure, epididymectomy, micro-denervation of the spermatic cord) are considered investigational; use of these procedures may result in claim denial.

    • Do not bill as medically necessary for indications listed as experimental/investigational in the policy
    • Anticipate potential denial if these procedures are performed for covered indications
    Denial Risk

    Limit routine opioid prescribing; document rationale if used

    Routine opioid prescribing after vasectomy is associated with increased risk of new persistent opioid use and other adverse outcomes; providers should limit opioid prescriptions and document the rationale when opioids are used.

    • Studies reported higher new persistent opioid use in opioid‑prescribed cohorts (e.g., 7.8% vs 1.5%)
    • Document necessity when prescribing opioids and follow guideline-recommended opioid stewardship
    Note

    Administrative metadata and review dates — verify plan rules

    Policy administrative metadata and review history are provided (Effective 12/07/2004; Last review 03/06/2023; Next review 01/11/2024); these chunks do not specify explicit procedural prior authorization or denial triggers — verify current administrative rules with the payer.

    • Effective date and review history are listed in the policy header
    • Administrative metadata does not replace checking plan-specific authorization requirements
    Described in clinical trials and ongoing research; chemicals/techniques for some vasal injections are not available for use in the U.S., and evidence is limited.
    MechanismPolymer injected into the vas lumen to impair or inhibit sperm transport/function without surgical occlusion.
    inv-28: LSVS (LigaSure vessel sealing system) — device definition and evaluation note
    DefinitionLigaSure vessel sealing system (LSVS): an electrosurgical vessel‑sealing device evaluated for occluding the vas deferens lumen as an alternative to standard ligation/cautery techniques.
    Evaluation noteEx vivo histopathology in one series showed higher total luminal occlusion rates with LSVS (79.5% for 5 mm and 89.4% for 10 mm) versus standard ligation techniques; further clinical studies are needed to confirm safety and efficacy.
    Policy statusListed among vasal occlusion methods considered experimental/investigational due to inadequate evidence.
    inv-29: MDSC — Micro-denervation of the spermatic cord definition
    DefinitionMicro‑denervation of the spermatic cord (MDSC): a surgical procedure that selectively denervates spermatic cord structures to treat post‑vasectomy pain syndrome.
    Outcomes evidenceIn a retrospective series (Tan et al), overall success (postoperative NRS ≤1) was 71% for treated testicular units, with higher success when multiple scrotal structures were involved.
    Policy statusListed among procedures for treatment of PVPS; considered investigational in the policy's experimental/investigational list.
    inv-30: VR — Vasectomy reversal definition (vasovasostomy/epididymovasostomy)
    DefinitionVasectomy reversal (VR): surgical restoration of vas deferens continuity, including vasovasostomy (VV) or epididymovasostomy (EV), intended to reestablish sperm transport.
    Procedures includedVasovasostomy (vasovasorrhaphy) and epididymovasostomy as techniques to restore vasal continuity.
    Therapeutic rolesPerformed to restore fertility and also used therapeutically for refractory post‑vasectomy pain syndrome in selected patients after conservative measures fail.
    inv-31: Post-vasectomy pain syndrome (alternate entry) — chronic testicular/scrotal pain description
    DescriptionChronic testicular or scrotal pain occurring after vasectomy that is distinct from expected post‑procedure discomfort; may present as a dull ache worsened by ejaculation and can impact quality of life.
    First‑line managementNonsteroidal anti‑inflammatory medications and warm baths; if unsuccessful, local nerve blocks or steroid injections are recommended prior to surgical options.
    Clinical relevancePVPS prevalence estimates vary; surveys report 'troublesome' post‑vasectomy pain in ~15% with severe impact in ~2%, while literature rates for PVPS are lower (~1–2%).
    inv-32: Vasectomy reversal (VR) — definition and therapeutic use for PVPS
    DefinitionVasectomy reversal (vasovasostomy or epididymovasostomy) performed to restore vasal continuity and used therapeutically to relieve PVPS in selected patients.
    Clinical outcomesSeries report variable pain‑relief success (e.g., vasovasostomy pain relief up to 70–82% in well‑selected patients; institutional series report substantial improvement in many patients).
    Documentation requirementsWhen VR is pursued for PVPS, documentation should show failure of conservative therapy (NSAIDs, nerve blocks/steroid injections), evaluation to exclude other causes of scrotal/testicular pain, and informed consent about variable success and need for alternative contraception.